Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines

The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm

Q28066714

The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: The clinical guidelines

Q28069743

The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future Research

Q28072601

The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of Guidelines

Q28076486

Evidence-based medicine. A new approach to teaching the practice of medicine

Q28190938

Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis

Q28245879

Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial

Q28259736

Trajectories of body mass index change in first episode of mania: 3-year data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).

Q31139867

Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in Korea

Q33662847

The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000.

Q33969206

Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines.

Q34025120

National trends in psychotropic medication polypharmacy in office-based psychiatry

Q34090959

Bipolar rapid cycling: focus on depression as its hallmark.

Q34317332

Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis

Q34349641

Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics

Q34405153

Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study

Q34474219

Practice guideline for the treatment of patients with bipolar disorder (revision)

Q95789383

Algorithm-driven treatment for bipolar disorder in Korea: Clinical feasibility, efficacy, and safety.

Q51857910

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Q52656684

Medication treatment of bipolar disorder 2000: a summary of the expert consensus guidelines.

Q53853216

Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision

Q59336772

Practice guideline for major depressive disorder in adults. American Psychiatric Association

Q70642428

Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association

Q72850842

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania

Q34531273

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment

Q34550618

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.

Q34588960

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania

Q34606256

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression

Q34616633

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder

Q34649187

Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology

Q34676317

Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis

Q34994544

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression

Q35024109

Korean Medication Algorithm Project for Bipolar Disorder: third revision

Q35142737

Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology

Q35180787

Olanzapine-valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group

Q35669961

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies

Q36161335

The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder.

Q36192638

Maintenance therapy with second generation antipsychotics for bipolar disorder - A systematic review and meta-analysis

Q36286584

Polytherapy in bipolar disorder

Q36361982

Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder

Q37407742

Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology

Q37426143

Role of atypical antipsychotics in rapid cycling bipolar disorder: a review of the literature.

Q37872620

Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy.

Q38243695

Atypical Anti-Psychotics in Adult Bipolar Disorder: Current Evidence and Updates in the NICE guidelines.

Q38270055

Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study

Q38381456

Is there consensus across international evidence-based guidelines for the management of bipolar disorder?

Q39161964

Factors associated with treatment nonadherence among US bipolar disorder patients

Q40146888

Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines.

Q41474591

Predictors of a Shorter Time to Hospitalization in Patients with Bipolar Disorder: Medication during the Acute and Maintenance Phases and Other Clinical Factors

Q41474674

Continuation and prophylactic treatment of bipolar disorder.

Q41588621

Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder

Q43130555

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

Q44142664

Korean medication algorithm for bipolar disorder: second revision.

Q44578637

Revised Korean medication algorithm for bipolar disorder.

Q45336273

Q45484599

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine

Q46921511

Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder

Q47696389

Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials

Q47925916

Clinical outcomes of long-acting injectable risperidone in patients with bipolar I disorder: A 1-year retrospective cohort study

Q48043570

THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS' PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS.

Q48079070

Korean Medication Algorithm for Depressive Disorders 2017: Third Revision.

Q48514039

A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.

Q48697520

P275

Creative Commons Attribution-NonCommercial 4.0 International

copyrighted

issue

language of work or name

English